The adhesion of HIV gp120 antigen to human cells is modulated in part by interactions with heparan sulfate. The HXB2 strain of gp120 has been shown to interact with heparin primarily through the V3 loop, although other domains including the C-terminal domain were also implicated. However, the JR-FL strain (representative of CCR5-interacting strains that make up newest infections) was shown to have a drastically lowered affinity to heparin due to the loss of several basic residues in the V3 loop, and deletion of the V3 loop in JR-FL gp120 was shown to abrogate some, but not all, heparin binding. Here, we use high resolution hydroxyl radical protein footprinting to measure the changes in protein surface oxidation levels that result from the binding of a model heparin fragment (fondaparinux). Protection in both the V3 loop and the N-terminus of JR-FP gp120 is observed. The well-defined composition of fondaparinux allowed us to perform docking simulations, which showed two clusters of fondaparinux binding: the V3 loop, and a domain consisting of the N-and C-termini. Together, the experimental and theoretical results indicate the heparin/heparan sulfate binding sites on JR-FL gp120 and the efficient interaction of fondaparinux, a widely exploited therapeutic carbohydrate, on gp120.
Introduction

Human immunodeficiency virus (HIV) enters the CD4
+ cells by interacting first with the primary receptor CD4 and then with a co-receptor, usually CXCR4 or CCR5 [1] . A glycoprotein, gp120, on the surface of HIV virus plays an important role in this process. Although gp120 consists of a polypeptide core of about 60 kDa, extensive N-linked glycosylation increases the molecular weight to approximately 120 kDa [2] . gp120 consists of five relatively conserved regions, C1 to C5, that fold into a core comprising two distinct domains termed "inner" and "outer", and five variable regions, V1 to V5 [3] . A number of studies [4, [5] [6] [7] have shown that when gp120 binds to CD4, the gp120 core structure undergoes structural rearrangements, and this is more prominent in the inner domain. Upon binding of gp120 to CD4, the base of the V1/V2 region of the inner domain consisting of β2 and β3 strands is brought closer to a hairpin turn of the outer domain consisting of β20 and β21 strands and forms a four-stranded β-sheet located within the bridging sheet that connects the inner and the outer domain. This highly conserved structure forms the binding site for CCR5 or CXCR4 in conjunction with the V3 loop, [8, [9] [10] [11] .
HIV virus can also infect CD4-cells by the interaction of gp120 with cell-surface associated heparan sulfate (HS) [12] . HS and the closely related heparin polysaccharide comprise a diverse family of heavily sulfated linear glycosaminoglycans (GAGs) that are covalently bound to proteins expressed on eukaryotic cell surfaces [13] . These GAGs have a variety of physiological and pathological functions, centered primarily on regulation of functional proteins. Signaling interactions occur between the cell surface GAGs and other cells or components of the extracellular matrix [14] . GAGs have been shown to play a variety of roles in HIV infection [4] .
The binding of heparin/HS polysaccharides to gp120 has been attributed mainly to interactions with the V3 loop of gp120 in the HXB2 strain (which uses the CXCR4 co-receptor), although other regions of the protein have also been implicated. Four heparin-binding domains (HBDs) in the HXB2 strain have been identified, located in the V2 and V3 loops, in the C-terminal domain, and within the CD-4 induced bridging sheet [5] . While protein-GAG interactions are commonly mediated by basic amino acids, the exact identity of amino acids of gp120 involved in this interaction is not known, and a complex mixture of heparin structures was used, making the detailed structure-function analysis not very accurate [5] . Additionally, the identified HBDs contain several basic residues that are missing in the commonly studied JR-FL strain, which uses the CCR5 co-receptor and is more indicative of viruses most commonly found in early and chronic stages of HIV infection [15] . Previous work indicated that heparin bound poorly to JR-FL compared to HXB2, indicating that the mutation of these residues probably plays a strong role in modulating the interaction of gp120 with heparin/HS. Interestingly, the binding that was detected for JR-FL appeared to be partially mediated by the V3 loop, but deletion of the V3 loop did not completely reduce heparin binding on gp120 to background levels [16] . This suggests that JR-FL gp120 interacts with heparin through multiple domains, complicating any analysis of these interactions. A structural approach examining the interaction between a defined heparin oligosaccharide ligand and gp120 from the JR-FL strain would give more accurate information on the resultant complex, especially if investigated by both experimental and computational modeling techniques. To develop an understanding of the structural basis for these interactions,
we employed a synthetic heparin oligosaccharide (fondaparinux) ligand and gp120 from the JR-FL strain in experimental hydroxyl radical protein footprinting (HRPF) analyses and computational docking studies that enabled us to fully define the binding modes.
Fondaparinux (Arixtra   ®   ) is a synthetic heparin pentasaccharide that has been previously used as a model heparin/HS oligosaccharide with defined structure (Figure 1 ), whose anticoagulant therapeutic activity derives from its ability to bind to antithrombin. Fondaparinux is a common oligosaccharide used in biophysical studies of GAG interactions with proteins, in which a readily available GAG oligosaccharide of the defined structure is required for the study [17, [18] [19] [20] . The synthetic pentasaccharide includes a 3-O-sulfated glucosamine, which has been implicated previously in adhesion of some viruses to cell surfaces [21, 22] . The experimental characterization and computational modeling of the contact sites between gp120 and fondaparinux will provide a better understanding of how gp120 interacts with fondaparinux and suggest possible methods for blocking the entry of the HIV virus into the host cells. configurations. GlcNS6S, GlcA, GlcNS3S6S and IdoA2S stand respectively for 2N-, 6O-disulfated glucosamine, glucuronic acid, 2N-, 3,6O-trisulfated glucosamine and 2O-sulfated iduronic acid.
In order to map the fondaparinux binding region of gp120, we performed high-resolution hydroxyl radical protein footprinting (HR-HRPF) by fast photochemical oxidation of proteins Some recent works from our group have established that using electron transfer dissociation (ETD)-based methods for quantifying multiple adjacent sites of isomeric oxidation products allows accurate quantification of changes in the HRPF down to single-amino acid spatial resolution providing structural information with higher spatial resolution and more accuracy [43, [44] [45] . Specific poses of the molecular interactions between a defined heparin oligosaccharide and gp120 can be developed by examining changes in the HR-HRPF of gp120 in the presence and in the absence of fondaparinux and comparing the generated results with computational docking simulations using a recently released model of the fully glycosylated JR-FL gp120 [43] .
Materials and Methods
Materials and Reagents
Purified JR-FL gp120 was purchased from Immune Technology Corp (New York, USA).
Fondaparinux, purchased from GlaxoSmithKline (Brentford, UK), was injected onto a Bio-Gel P-2 (Bio-Rad, USA) size exclusion column and eluted with milli-Q water at a flow rate of 1 mL/7.5 min for desalting and further purification. Fractions of 20 mL were collected and assayed by metachromasia using 1 mL of 1,9-dimethylmethylene blue (DMB). 
FPOP of gp120-Fondaparinux
FPOP was performed as previously described [33] . Briefly, a final concentration of 2 µM gp120 Samples were stored at -20 °C until analysis was performed on nano-LC-MS/MS system.
Mass Spectrometry
The protein samples were analyzed on an Orbitrap Fusion instrument (Thermo Fisher Scientific) controlled with Xcalibur version 2.0.7 (Thermo Fisher, San Jose, CA). Samples were loaded onto an Acclaim PepMap 100 C18 nanocolumn (0.75 mm × 150 mm, 2 μm, Thermo Fisher Scientific). Separation of peptides on the chromatographic system was performed using mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile) at a rate of 300 μL/min. The peptides were eluted with a gradient consisting of 2 to 35% solvent B over 25 min, ramped to 95 % B over 3 min, held for 3 min, and then returned to 2% B over 3 min and held for 8 min. Peptides were eluted directly into the nanospray source of an Orbitrap Fusion instrument using a conductive nanospray emitter obtained from Thermo Scientific. All data were acquired in positive ion mode. Both collision-induced dissociation (CID) and ETD were used to fragment peptides, with an isolation width of 3 m/z units. The spray voltage was set to 2300
volts, and the temperature of the heated capillary was set to 300 °C. In CID mode, full MS scans were acquired from m/z 200 to 2000 followed by eight subsequent MS2 scans on the top eight most abundant peptide ions. In ETD mode, the parent ions of all identified peptides were included in the parent mass list. ETD-based precursor activation was performed for 100 ms, including charge state-dependent with supplemental activation of 5V CID energy.
HR-HRPF Data Analysis
Unoxidized gp120 controls, oxidized gp120, and oxidized complex of gp120-fondaparinux complex peptide sequences were initially identified using ByOnic version v2.10.5 (Protein Metrics) using gp120 JR-FL sequence database. The enzyme specificity was set to cleave the protein after lysine and arginine. Deamination on both asparagine and glutamine and all possible major oxidation modifications [47] were included as variable modifications for database searches. All tandem mass spectral assignments and sites of oxidation were verified manually.
The peak intensities of the unoxidized peptides and their corresponding oxidation products observed in LC-MS were used to calculate the average oxidation events per peptide in the sample. Peptide level oxidation was calculated by adding the ion intensities of all the oxidized peptides multiplied by the number of oxidation events required for the mass shift (e.g., one event for +16, two events for +32) and then divided by the sum of the ion intensities of all unoxidized and oxidized peptide masses as represented by equation 1.
. where P denotes the oxidation events at the peptide level and I values are the peak intensities of oxidized and unoxidized peptides. gp120 control samples that were not exposed to laser irradiation, but identical to the experimental samples otherwise, were analyzed to ensure that background oxidation would not be high enough to interfere with HR-HRPF data. These control samples showed <8% of the oxidation extent of the gp120 sample (data not shown). The interference of this small background is not significant enough to affect the comparison of the oxidation extent between gp120 and gp120-fondaparinux samples.
In cases in which oxidation at specific sites can be identified on the basis of either the mass differences between nonisomeric oxidation products or the presence of only a single oxidation site within a peptide as confirmed by CID and/or ETD, residue level quantitation is calculated from the LC-MS signal intensities of each peptide containing a specific oxidized amino acid (Ioxidized), relative to the total of all intensities associated with that peptide sequence (Ioxidized +Iunoxidized) according to equation2:
In cases where oxidation of a peptide results in a mixture of isomers with oxidation at different sites, residue level quantitation is calculated from the fragment ion intensities from ETD to determine the oxidation extent at a specific residue site based on our previous studies [33, 43] .
Briefly, an oxidized peptide with multiple sites of oxidation can generate both oxidized and unoxidized sequence ions in its tandem mass spectrum. The fractional oxidation of a given sequence ion is defined as the ratio between the oxidized sequence ion intensity and the sum of the intensity of the corresponding oxidized and unoxidized sequence ion as represented in
Here, f(Ci) denotes the fractional oxidization of sequence ion I (e.g., oxidized C3 ions generated by ETD) and I(Ci) denotes the intensity of sequence ion i, whether it is the oxidized or unoxidized form. The absolute level of oxidation for a given amino acid residue i is based on both the average oxidation event of the peptide and the fractional oxidation of the corresponding sequence ions, as shown in equation 4:
where P is the average oxidation events per peptide as derived from eq 1 and the term in brackets is the fractional oxidation difference of two adjacent sequence ions i and i -1. The multiplication of the average number of oxidations per peptide by the fraction of that oxidation that occurs on a given amino acid residue yields the average oxidation events per residue. The protection by fondaparinux binding is defined as the ratio of the difference in oxidation extent between the gp120 sample alone and the gp120-fondaparinux binding sample to the oxidation extent of the gp120 sample alone. This is shown in eq 5:
gp120-Fondaparinux Complex Docking
The glycosylated model of gp120 previously published [43] was modified by the addition of the terminal structure from a previously published crystal structure of JR-FL SOSIP.664 (PDB ID: 5FYK) [48] . The termini were minimized in vacuo by steepest descent minimization for 5000 steps followed by 20000 steps of conjugate gradient minimization with the sander.MPI version of AMBER14 [49] using the Amber ff14SB force field. The resulting model was used for docking. The three-dimensional structures of fondaparinux, one with IdoA in 1 C4 chair configuration and the other with IdoA in 2 S0 skewed-boat configuration were generated using GLYCAM-Web server (www.glycam.org).
Docking was performed using Autodock 4.2.6 (AD4.2.6) [50] and Autodock Vina 1.1.2 (ADV) [51] . All input files were prepared for docking using AutoDock Tools 1.5.6 (ADT) [50] . For blind docking (entire protein surface used as the search space) with AD4.2.6, Gasteiger charges [52] were assigned to prepare protein and ligands and a grid box with 1Å spacing was employed for all runs, centered at the gp120 protein center. 100 runs of the Lamarckian Genetic Algorithm were performed, with 2,500,000 energy evaluations per run, and a population size of 200. For targeted docking with ADV, the exhaustiveness value was set to 80, while all the other parameters were set to their default values. Both the protein and ligand remain rigid for docking in all cases. VMD [53] was used to calculate the average structure, the center of the structure and for image rendering.
Solvent accessibility surface area (SASA) was calculated using NACCESS [54] program. Perresidue relative SASA was used for the analysis. Docking poses representing the lowest energy configurations of the iduronic acid in either the 1 C4 or 2 S0 configurations at the two docking cluster sites were shown using PyMol. 
Results
HR-HRPF of JR-FL gp120 and the JR-FL gp120-Fondaparinux
Docking of fondaparinux with JR-FL gp120
Previous work from our group generated a glycosylated model of JR-FL gp120 [43] . However, this model lacked the N-and C-termini of the JR-FL structure, due to their absence in the template structure. Given the protection of amino acids at the extreme N-terminus of JR-FL gp120 upon fondaparinux binding, the N-and C-termini modeled from a recent X-ray crystal structure of JR-FL SOSIP.664 (PDB ID: 5FYK) [48] were added to our previously published model and minimized. Fondaparinux was docked to this model in two separate blind docking runs using AD4.2.6: one with the iduronic acid in the 1 C4 chair conformation and one with it in the 2 S0 skew-boat form. In both the cases, the docked structures clustered on either the electropositive patch close to the V3 region of gp120 (site 1) or at the patch formed by both the N-and C-terminal region (site 2) ( Figure 5) . Targeted docking was then performed using ADV, by placing a grid box of size 30 × 30 × 30Å at the center of the cluster from the previous step ( Figure 6 ). Ligand binding shields protein residues from interacting with the solvent. Therefore, this shielding can be used to specify the protein region involved in docking. These data also reflect the experimental changes that are measured by HR-HRPF [55, 56] . Changes in solvent accessibility were estimated using the difference between the SASA values of unbound and Table 1 .
Discussion
The (Figure 7) . This ionic interaction does not appear to be an artifact of the molecular dynamics simulation; it is also present in the recent X-ray crystal structure of the As mentioned by Lortat-Jacob and co-workers, JR-FL gp120 is missing several basic residues in the V3 loop that are thought to drive binding of heparin to this domain in CXCR4-binding strains, and as a result, has a much lower binding affinity that is only partially dictated by the V3 loop [16] . We hypothesize that it is the reduction of affinity in this high-affinity binding site that This terminal binding domain is probably inclusive of the C-terminal HBD described for HXB2 gp120, as the N-terminus detected by HR-HRPF here as a binding site for fondaparinux forms a two-strand anti-parallel beta-sheet with the C-terminus, holding the residues identified as protected in the N-terminus here by HR-HRPF in direct proximity to the C-terminal HBD3
identified by Lortat-Jacob and coworkers [5] . We further hypothesize that this terminal domain is the major contributor to heparin binding above background in JR-FL with the V3 loop deleted [16] .
It should be noted that previous work on the interaction of full-length heparin with Robo1 found two distal sites of heparin binding, one at an internal flexible region and one at the N-terminus.
Mutation of either of the two binding sites decreased the affinity of Robo1 to heparin by a similar amount, illustrating the role of avidity in the binding of these long polysaccharides to multiple binding sites of a single protein [33] . We hypothesize that these two distal binding sites may play a similar role in gp120, where tethering of the gp120 to a heparin/HS polysaccharide at one of the two gp120 heparin binding sites increases the binding at the second binding site, and engagement of both binding sites increases the functional affinity of gp120 on the cell surface polysaccharide. HR-HRPF of JR-FL gp120 complexed with full-length heparin may be informative; however, computational modeling of such a system becomes less useful due to the heterogeneity and polydispersity of heparin, and the size of the gp120-heparin complexes.
Our data, supported by blind docking, indicate that fondaparinux in an equimolar ratio can bind to JR-FL gp120 at low micromolar concentrations in sufficient amounts to detect using HR- 
